Liftstream is an executive search recruitment company in the life sciences sector
Nominations Committees’ Resolutions Series: #1- Board and Executive Succession Planning Must Be Forward Looking
Succession Planning should concern the nomination committee all year round, but the ticking over of the calendar is the perfect opportunity to appraise the sophistication of your succession planning.
Codiak BioSciences, a venture-backed start-up in Cambridge, Mass, has appointed Ariel Jasie as Chief Business Officer, Linda Bain as CFO and Konstantin Konstantinov as Senior Vice President.
Thursday, December 3, 2015 from 4:00 PM to 7:30 PM (EST)
Biogen, Bio-9 Building, 300 Binney Street Cambridge, MA 02142 – View Map
Just days after setting the terms for its pending IPO, Dimension Therapeutics, Inc., a leading rare disease company advancing novel, liver-directed treatments for diverse genetic disorders, announced the election of Alan B. Colowick, M.D., M.P.H., Executive Vice President of Celgene Corporation, to Dimension’s Board of Directors. Dr. Colowick brings strong operational expertise and more than 15 years of experience in biopharmaceutical development. His election to the company’s Board is effective immediately.
Celgene has announced the appointment of Julia Haller, M.D, to the Board of Directors. The appointment means Celgene now has three females on the board and reaches a 33% ratio of women non-executive board directors, a critical mass that is likely to drive a significant advantage for the way in which Celgene is governed and also contribute to a sustainable level of diversity. With strong advocates for gender diversity on its board, such as Michael Bonney and Richard Barker, Celgene is showing that it is very much possible to create a gender diverse board of directors in biotechnology.
The trajectory of biotech M&A has been steep in 2015, so the $7.2bn acquisition of Receptos by oncology powerhouse Celgene, increases the gradient even further. This deal came out of left field, especially as commentators were still raking over the sizable partnering deal Celgene has just cemented with Juno Therapeutics in immuno-oncology.
Authored by Karl Simpson – April 2013
Authored by James Sheppard